
INAB
IN8bio Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.4855
Open
2.480
VWAP
2.40
Vol
99.29K
Mkt Cap
39.68M
Low
2.345
Amount
238.73K
EV/EBITDA(TTM)
--
Total Shares
44.12M
EV
-3.75M
EV/OCF(TTM)
--
P/S(TTM)
--
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-1.800
-68.42%
--
--
-1.600
-64.44%
--
--
-1.400
+16.67%
Estimates Revision
The market is revising No Change the revenue expectations for IN8bio, Inc. (INAB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -57.57%.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change

0.00%
In Past 3 Month
Stock Price
Go Down

-57.57%
In Past 3 Month
3 Analyst Rating

3717.43% Upside
Wall Street analysts forecast INAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INAB is 92.00 USD with a low forecast of 36.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy

3717.43% Upside
Current: 2.410

Low
36.00
Averages
92.00
High
180.00

3717.43% Upside
Current: 2.410

Low
36.00
Averages
92.00
High
180.00
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Maintains
$8 → $6
2025-03-14
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$8 → $6
2025-03-14
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$8
2025-02-12
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$8
2025-02-12
Reiterates
Strong Buy
Reason
Jones Trading
Soumit Roy
Hold
to
Strong Buy
Upgrades
$1.2
2025-02-11
Reason
Jones Trading
Soumit Roy
Price Target
$1.2
2025-02-11
Upgrades
Hold
to
Strong Buy
Reason
JonesResearch analyst Soumit Roy upgraded IN8bio to Buy from Hold with a $1.20 price target.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$8
2024-11-26
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$8
2024-11-26
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Maintains
$13 → $8
2024-11-13
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$13 → $8
2024-11-13
Maintains
Strong Buy
Reason
Jones Trading
Soumit Roy
Strong Buy
to
Hold
Downgrades
n/a
2024-08-12
Reason
Jones Trading
Soumit Roy
Price Target
n/a
2024-08-12
Downgrades
Strong Buy
to
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for IN8bio Inc (INAB.O) is -0.51, compared to its 5-year average forward P/E of -2.18. For a more detailed relative valuation and DCF analysis to assess IN8bio Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-2.18
Current PE
-0.51
Overvalued PE
-0.68
Undervalued PE
-3.68
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-0.13
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.24
Undervalued EV/EBITDA
-0.49
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.04
Undervalued PS
-0.04
Financials
Annual
Quarterly
FY2025Q1
YoY :
-34.53%
-5.66M
Operating Profit
FY2025Q1
YoY :
-35.18%
-5.55M
Net Income after Tax
FY2025Q1
YoY :
-65.00%
-0.07
EPS - Diluted
FY2025Q1
YoY :
-60.93%
-3.12M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 2792.5% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
INAB News & Events
Events Timeline
2025-06-09 (ET)
2025-06-09
07:17:38
IN8bio recognizes 4-years in remission for patient treated with INB-200

2025-06-02 (ET)
2025-06-02
07:47:20
IN8bio presents Phase 1 data on INB-200 in newly diagnosed GBM

2025-05-14 (ET)
2025-05-14
08:11:33
IN8bio announces preclinical data from its INB-619 program

Sign Up For More Events
Sign Up For More Events
News
4.5
06-09BenzingaUS Stocks Likely To Open On A Mixed Note After S&P 500 Scales 6,000-Mark: 'Whole Globe Is In A Bull Market'
9.0
06-02NewsfilterIN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
9.0
05-14NewsfilterIN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025
Sign Up For More News
People Also Watch

NWGL
Nature Wood Group Ltd
1.030
USD
-0.96%

SNTI
Senti Biosciences Inc
1.990
USD
-2.93%

EVTV
Envirotech Vehicles Inc
0.190
USD
-1.04%

PSHG
Performance Shipping Inc
1.898
USD
-0.11%

MSS
Maison Solutions Inc
0.916
USD
-0.65%

YI
111 Inc
7.380
USD
+0.41%

RAY
Raytech Holding Ltd
2.620
USD
+0.77%

CDIO
Cardio Diagnostics Holdings Inc
4.580
USD
+3.85%

MOB
Mobilicom Ltd
3.680
USD
0.00%

CARA
Cara Therapeutics Inc
15.870
USD
-4.32%
FAQ

What is IN8bio Inc (INAB) stock price today?
The current price of INAB is 2.41 USD — it has decreased -2.03 % in the last trading day.

What is IN8bio Inc (INAB)'s business?

What is the price predicton of INAB Stock?

What is IN8bio Inc (INAB)'s revenue for the last quarter?

What is IN8bio Inc (INAB)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for IN8bio Inc (INAB)'s fundamentals?

How many employees does IN8bio Inc (INAB). have?
